trending Market Intelligence /marketintelligence/en/news-insights/trending/K2aM9UdGj1GzQC3KsQei1w2 content esgSubNav
In This List

Allergan settling patent litigation with InnoPharma over dry eye drug Restasis

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Allergan settling patent litigation with InnoPharma over dry eye drug Restasis

Allergan plc reached an agreement to resolve its patent litigation with Innopharma Inc. related to six patents on dry eye drug Restasis.

The patents are listed in the Orange Book and expire Aug. 27, 2024.

Under the settlement, all InnoPharma Hatch-Waxman litigation related to Restasis patents will be dismissed. Allergan will also grant InnoPharma licenses to market a generic version of Restasis in the U.S., starting Feb. 24, 2024, or earlier under certain circumstances.

In addition, under certain circumstances, the company will supply and authorize InnoPharma to launch an authorized generic version of Restasis on Aug. 28, 2024.

Additional details regarding the settlement were not disclosed.